Severity
Moderate
ModerateClass IIOngoing
FDA Drug recall · Reported May 13, 2026
NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16
Chemical contamination; presence of lead and lithium above specification
Acella Pharmaceuticals, LLC recalled NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed… - a moderate-severity action.
NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed… was recalled by Acella Pharmaceuticals, LLC in May 13, 2026. Reason: Chemical contamination; presence of lead and lithium above specification. Check the official notice for the remedy. Verify recall #D-0523-2026 with the FDA Drug before acting.
The recall
Acella Pharmaceuticals, LLC issued this moderate-severity FDA Drug recall-Chemical contamination; presence of lead and lithium above specification.
- Moderate
- severity level
- Class II
- classification
- May 13, 2026
- reported
Sourced from official FDA Drug enforcement records. Verify recall #D-0523-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
Recall Insight
This FDA Drug action (record #D-0523-2026) was formally reported on May 13, 2026, with the manufacturer initiating the action on April 20, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Acella Pharmaceuticals, LLC is listed as the recalling firm, operating out of Alpharetta, GA. Federal records list the affected scope as 6,336 bottles.
The documented reason for this recall is: Chemical contamination; presence of lead and lithium above specification Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Electronics recalls over time
Where this recall sits in its category - 609 electronics recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Affected scope
6,336 bottles
Related Recalls
6
0 from same agency
Product description
NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16
Reason for recall
Chemical contamination; presence of lead and lithium above specification
Recall Profile
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0523-2026 |
| Date reported | May 13, 2026 |
| Date initiated | April 20, 2026 |
| Recalling firm | Acella Pharmaceuticals, LLC |
| Firm location | Alpharetta, GA |
| Affected scope | 6,336 bottles |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
- Check the recall number (D-0523-2026) and product description against the item you own. Search the archive
- Confirm the current status with FDA Drug before acting, recall details can be updated.
- Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Frequently Asked Questions
What product was recalled? ▼
NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16. Recalled by Acella Pharmaceuticals, LLC. Units affected: 6,336 bottles.
Why was this product recalled? ▼
Chemical contamination; presence of lead and lithium above specification
Which agency issued this recall? ▼
This recall was issued by the FDA Drug on May 13, 2026. Severity: Moderate. Recall number: D-0523-2026.
Where was the recalled product distributed? ▼
Distribution: Nationwide.
How do I check if my product is affected by a recall? ▼
Check the product description and recall number (D-0523-2026) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device? ▼
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.
Nearby Recalls in This Category
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
CPSC Moderate
Projecting LED Finger Light Toys Recalled Due to Risk of Serious Injury Death from Battery Ingestion; Violate Mandatory…
Shenzhen Bopu Product Design Co., Ltd., dba POPOOO, of China · 2026-07-02
CPSC Moderate
Combination Smoke and Carbon Monoxide (CO) Detectors Recalled Due to Risk of Serious Injury or Death from Failure to Al…
· 2026-06-25
CPSC Moderate
Raychy Children's Light Sneakers Recalled Due to Risk of Serious Injury or Death from Battery Ingestion; Violate Mandat…
· 2026-06-25
CPSC Moderate
Super Off-Road Solar Power Banks Recalled Due to Overheating; Imported by Spector & Co.
· 2026-06-25
CPSC Moderate
School Specialty Recalls Tip Restraint Kits Included in Childcraft Furniture Due to Risk of Serious Injury or Death fro…
School Specialty, LLC, of Greenville, Wisconsin · 2026-06-11
Compare this recall with Projecting LED Finger Light Toys Recalled Due to Risk of Se… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 13, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.